Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen T Keir

Showing results (1-10 of 129) with videos related to

Pageof 13
Sort By:
Cancer Nursing|November 21, 2007
Levels of stress and intervention preferences of caregivers of brain tumor patientsStephen T Keir
Clinical Journal of Oncology Nursing|October 27, 2007
Program preferences to reduce stress in caregivers of patients with brain tumorsJonas J Swartz, Stephen T Keir
Anticancer Research|December 29, 2010
Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human brain tumor modelsIdoia Gamez, Robert P Ryan, Stephen T Keir
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 5, 2007
Stress and long-term survivors of brain cancerStephen T Keir, Jonas J Swartz, Henry S Friedman
Cancer|April 25, 2003
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumorsHenry S Friedman, Stephen T Keir, Peter J Houghton
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 31, 2006
Stress and intervention preferences of patients with brain tumorsStephen T Keir, Ann Bebe Guill, Karen E Carter, et al.
Journal of Cancer Survivorship : Research and Practice|October 30, 2008
Distress persists in long-term brain tumor survivors with glioblastoma multiformeStephen T Keir, Margaret M Farland, Eric S Lipp, et al.
Journal of Neuro-Oncology|August 19, 2018
Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E statusEric M Thompson, Daniel Landi, David Ashley, et al.
Current Radiopharmaceuticals|January 19, 2011
[Lu]-DOTA-Tyr-octreotate: A Potential Targeted Radiotherapeutic for the Treatment of MedulloblastomaGanesan Vaidyanathan, Donna J Affleck, Xiao-Guang Zhao, et al.
Oncotarget|May 20, 2015
Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapiesKingshuk Roy Choudhury, Stephen T Keir, Kathleen A Ashcraft, et al.
Pageof 13

Showing results (1-10 of 129) with videos related to

Sort By:
Pageof 13
Cancer Nursing|November 21, 2007
Levels of stress and intervention preferences of caregivers of brain tumor patientsStephen T Keir
Clinical Journal of Oncology Nursing|October 27, 2007
Program preferences to reduce stress in caregivers of patients with brain tumorsJonas J Swartz, Stephen T Keir
Anticancer Research|December 29, 2010
Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human brain tumor modelsIdoia Gamez, Robert P Ryan, Stephen T Keir
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 5, 2007
Stress and long-term survivors of brain cancerStephen T Keir, Jonas J Swartz, Henry S Friedman
Cancer|April 25, 2003
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumorsHenry S Friedman, Stephen T Keir, Peter J Houghton
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 31, 2006
Stress and intervention preferences of patients with brain tumorsStephen T Keir, Ann Bebe Guill, Karen E Carter, et al.
Journal of Cancer Survivorship : Research and Practice|October 30, 2008
Distress persists in long-term brain tumor survivors with glioblastoma multiformeStephen T Keir, Margaret M Farland, Eric S Lipp, et al.
Journal of Neuro-Oncology|August 19, 2018
Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E statusEric M Thompson, Daniel Landi, David Ashley, et al.
Current Radiopharmaceuticals|January 19, 2011
[Lu]-DOTA-Tyr-octreotate: A Potential Targeted Radiotherapeutic for the Treatment of MedulloblastomaGanesan Vaidyanathan, Donna J Affleck, Xiao-Guang Zhao, et al.
Oncotarget|May 20, 2015
Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapiesKingshuk Roy Choudhury, Stephen T Keir, Kathleen A Ashcraft, et al.
Pageof 13